



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	110621	Qian Lie Kang a.k.a. Phellodendron & Cyathula Free Flow Formula
ARTG entry for	Medicine Listed	
Sponsor	Sun Herbal Pty Ltd	
Postal Address	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
ARTG Start Date	30/09/2004	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Qian Lie Kang a.k.a. Phellodendron & Cyathula Free Flow Formula

Product Type	Single Medicine Product	Effective Date	12/04/2018
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Traditionally used in Chinese medicine to invigorate/activate Blood

Traditionally used in Chinese medicine to eliminate/reduce/remove/resolve/dissipate blood-stasis

Traditionally used in Chinese medicine to clear/dry/drain/eliminate/resolve dampness in/of Disorders of the Lower Jiao (Burner) pattern

Traditionally used in Chinese medicine to dispel/expel/disperse/clear internal/endogenous heat in/of Disorders of the Lower Jiao (Burner) pattern

Traditionally used in Chinese medicine to nourish/tonify/replenish kidney-yin

Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to kidney disease.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Alisma plantago aquatica rhizome Extract dry concentrate	26.87 mg
Equivalent: Alisma plantago aquatica (Dry)	162 mg
Anemarrhena asphodeloides rhizome Extract dry concentrate	26.87 mg
Equivalent: Anemarrhena asphodeloides (Dry)	162 mg
Cornus officinalis fruit Extract dry concentrate	23.88 mg
Equivalent: Cornus officinalis (Dry)	144 mg
Cyathula officinalis root Extract dry concentrate	26.87 mg
Equivalent: Cyathula officinalis (Dry)	162 mg
Glycyrrhiza uralensis root Extract dry concentrate	11.94 mg
Equivalent: Glycyrrhiza uralensis (Dry)	72 mg
Lindera strychnifolia root Extract dry concentrate	26.87 mg
Equivalent: Lindera strychnifolia (Dry)	162 mg
Paeonia obovata root Extract dry concentrate	26.87 mg
Equivalent: Paeonia obovata (Dry)	162 mg
Paeonia suffruticosa stem bark Extract dry concentrate	26.87 mg
Equivalent: Paeonia suffruticosa (Dry)	162 mg
Phellodendron amurense stem bark Extract dry concentrate	26.87 mg
Equivalent: Phellodendron amurense (Dry)	162 mg
Rehmannia glutinosa root Extract dry concentrate	41.79 mg
Equivalent: Rehmannia glutinosa (Dry)	252 mg
Wolfiporia cocos fruiting body Extract dry concentrate	32.84 mg
Equivalent: Wolfiporia cocos (Dry)	198 mg

Other Ingredients (Excipients)

hydrolysed gelatin
soluble maize starch
titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary